JFGIW
LGND icon

Johnson Financial Group Inc (Wisconsin)’s Ligand Pharmaceuticals LGND Stock Holding History

Johnson Financial Group Inc (Wisconsin)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-130
Closed -$9.29K – 904
2023
Q4 		$9.29K Buy
+130
New +$7.67K ﹤0.01% 663

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Johnson Financial Group Inc (Wisconsin)'s LGND Position: Q1 2024 in Review

Johnson Financial Group Inc (Wisconsin) sold out of Ligand Pharmaceuticals (LGND) in Q1 2024, closing a stake of 130 shares — an estimated $9.29K sold.

Johnson Financial Group Inc (Wisconsin) first reported a position in LGND in Q4 2023 and held it in 1 quarter. The position peaked at $9.29K in Q4 2023. 222 funds tracked by Wall St. Rank hold LGND as of Q1 2024.

  • Johnson Financial Group Inc (Wisconsin) reported no remaining Ligand Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Johnson Financial Group Inc (Wisconsin) sold 130 Ligand Pharmaceuticals shares in Q1 2024, an estimated $9.29K.
  • Johnson Financial Group Inc (Wisconsin) first reported a position in Ligand Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Johnson Financial Group Inc (Wisconsin)'s Ligand Pharmaceuticals position peaked at $9.29K in Q4 2023.
  • 222 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2024.

Based on Johnson Financial Group Inc (Wisconsin)'s 13F filing for Q1 2024, filed 14 May 2024.